Functional Inhibition of VEGF and EGFR Suppressors in Cancer Treatment

Author(s): Anuraj Nayarisseri, Sanjeev Kumar Singh.

Journal Name: Current Topics in Medicinal Chemistry

Volume 19 , Issue 3 , 2019

Become EABM
Become Reviewer

[1]
Tabernero, J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res., 2007, 5(3), 203-220. [http://dx.doi.org/10.1158/1541-7786.MCR-06-0404]. [PMID: 17374728].
[2]
Pabla, B.; Bissonnette, M.; Konda, V.J. Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention. World J. Clin. Oncol., 2015, 6(5), 133-141. [http://dx.doi.org/10.5306/wjco.v6.i5.133]. [PMID: 26468449].
[3]
Lurje, G.; Lenz, H-J. EGFR signaling and drug discovery. Oncology, 2009, 77(6), 400-410. [http://dx.doi.org/10.1159/000279388]. [PMID: 20130423].
[4]
Seshacharyulu, P.; Ponnusamy, M.P.; Haridas, D.; Jain, M.; Ganti, A.K.; Batra, S.K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets, 2012, 16(1), 15-31. [http://dx.doi.org/10.1517/14728222.2011.648617]. [PMID: 22239438].
[5]
Gudala, S.; Khan, U.; Kanungo, N.; Bandaru, S.; Hussain, T.; Parihar, M.; Nayarisseri, A.; Mundluru, H.P. Identification and pharmacological analysis of high efficacy small molecule inhibitors of EGF-EGFR interactions in clinical treatment of non-small cell lung carcinoma: A computational approach. Asian Pac. J. Cancer Prev., 2015, 16(18), 8191-8196. [http://dx.doi.org/10.7314/APJCP.2015.16.18.8191]. [PMID: 26745059].
[6]
Gross-Goupil, M. Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin. Med. Insights Oncol., 2013, 7, S10594.
[7]
Sharma, K. Structure base Virtual screening for the identification of high affinity compounds as potent VEGFR2 inhibitors for the treatment of renal cell carcinoma. Curr. Top. Med. Chem., 2018.
[8]
Kilfoy, B.A.; Zheng, T.; Holford, T.R.; Han, X.; Ward, M.H.; Sjodin, A.; Zhang, Y.; Bai, Y.; Zhu, C.; Guo, G.L.; Rothman, N.; Zhang, Y. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control, 2009, 20(5), 525-531. [http://dx.doi.org/10.1007/s10552-008-9260-4]. [PMID: 19016336].
[9]
Dunna, N.R.; Kandula, V.; Girdhar, A.; Pudutha, A.; Hussain, T.; Bandaru, S.; Nayarisseri, A. High affinity pharmacological profiling of dual inhibitors targeting RET and VEGFR2 in inhibition of kinase and angiogeneis events in medullary thyroid carcinoma. Asian Pac. J. Cancer Prev., 2015, 16(16), 7089-7095. [http://dx.doi.org/10.7314/APJCP.2015.16.16.7089]. [PMID: 26514495].
[10]
Nayarisseri, A. In silico investigations on HSP90 and its inhibition for the therapeutic prevention of breast cancer. J. Pharm. Res., 2013, 7(2), 150-156. [http://dx.doi.org/10.1016/j.jopr.2013.02.020].
[11]
Vuree, S. Pharmacogenomics of drug resistance in Breast Cancer Resistance Protein (BCRP) and its mutated variants. J. Pharm. Res., 2013, 6(7), 791-798. [http://dx.doi.org/10.1016/j.jopr.2013.06.020].
[12]
Patidar, K.; Deshmukh, A.; Bandaru, S.; Lakkaraju, C.; Girdhar, A.; Vr, G.; Banerjee, T.; Nayarisseri, A.; Singh, S.K. Virtual screening approaches in identification of bioactive compounds akin to delphinidin as potential HER2 inhibitors for the treatment of breast cancer. Asian Pac. J. Cancer Prev., 2016, 17(4), 2291-2295. [http://dx.doi.org/10.7314/APJCP.2016.17.4.2291]. [PMID: 27221932].
[13]
Praseetha, S.; Bandaru, S.; Nayarisseri, A.; Sureshkumar, S. Pharmacological analysis of vorinostat analogues as potential anti-tumor agents targeting human histone deacetylases: An epigenetic treatment stratagem for cancers. Asian Pac. J. Cancer Prev., 2016, 17(3), 1571-1576. [http://dx.doi.org/10.7314/APJCP.2016.17.3.1571]. [PMID: 27039807].
[14]
Sharda, S.; Sarmandal, P.; Cherukommu, S.; Dindhoria, K.; Yadav, M.; Bandaru, S.; Sharma, A.; Sakhi, A.; Vyas, T.; Hussain, T.; Nayarisseri, A.; Singh, S.K. A virtual screening approach for the identification of high affinity small molecules targeting BCR-ABL1 inhibitors for the treatment of chronic myeloid leukemia. Curr. Top. Med. Chem., 2017, 17(26), 2989-2996. [http://dx.doi.org/10.2174/1568026617666170821124512]. [PMID: 28828991].
[15]
Nasr, A.B.; Ponnala, D.; Sagurthi, S.R.; Kattamuri, R.K.; Marri, V.K.; Gudala, S.; Lakkaraju, C.; Bandaru, S.; Nayarisseri, A. Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions. Bioinformation, 2015, 11(6), 307-315. [http://dx.doi.org/10.6026/97320630011307]. [PMID: 26229292].
[16]
Sinha, K.; Majhi, M.; Thakur, G.; Patidar, K.; Sweta, J.; Hussain, T.; Nayarisseri, A.; Singh, S.K. Computer aided Drug Designing for the identification of high affinity small molecule targeting CD20 for the clinical treatment of Chronic Lymphocytic Leukemia (CLL). Curr. Top. Med. Chem., 2018, 18(29), 2527-2542. [http://dx.doi.org/10.2174/1568026619666181210150044]. [PMID: 30526461].
[17]
Khandelwal, R.; Chauhan, A.P.S.; Bilawat, S.; Gandhe, A.; Hussain, T.; Hood, E.A.; Nayarisseri, A.; Singh, S.K. Structure-based virtual screening for the identification of high affinity small molecule towards STAT3 for the clinical treatment of Osteosarcoma. Curr. Top. Med. Chem., 2018, 18(29), 2511-2526. [http://dx.doi.org/10.2174/1568026618666181115092001]. [PMID: 30430945].
[18]
Bandaru, S.; Sumithnath, T.G.; Sharda, S.; Lakhotia, S.; Sharma, A.; Jain, A.; Hussain, T.; Nayarisseri, A.; Singh, S.K. Helix-coil transition signatures B-Raf V600E mutation and virtual screening for inhibitors directed against mutant B-Raf. Curr. Drug Metab., 2017, 18(6), 527-534. [http://dx.doi.org/10.2174/1389200218666170503114611]. [PMID: 28472910].
[19]
Rao, D.M. Comparative modeling of methylentetrahydrofolate reductase (MTHFR) enzyme and its mutational assessment: in silico approach. Int. J. Bioinform. Res., 2010, 2(1), 5-9. [http://dx.doi.org/10.9735/0975-3087.2.1.5-9].
[20]
Sinha, C.; Nischal, A.; Bandaru, S.; Kasera, P.; Rajput, A.; Nayarisseri, A.; Khattri, S. An in silico approach for identification of novel inhibitors as a potential therapeutics targeting HIV-1 viral infectivity factor. Curr. Top. Med. Chem., 2015, 15(1), 65-72. [http://dx.doi.org/ 10.2174/1568026615666150112114337]. [PMID: 25579575].


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 3
Year: 2019
Page: [178 - 179]
Pages: 2
DOI: 10.2174/156802661903190328155731

Article Metrics

PDF: 40
HTML: 4

Special-new-year-discount